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DEAR EDITOR, Lentigo maligna (LM) is a melanoma in situ, and its
incidence is still rising in the Netherlands.1 LM is located mostly
in the face, and therefore radical surgical removal, which is the
first choice of treatment, can be challenging in this delicate
anatomical region. Staged excision is considered a useful alter-
native. The initial diagnosis of clinically suspicious LM is usually
based on just one or a few biopsies, which may lead to reclassi-
fication into lentigo maligna melanoma (LMM) based on histo-
logical evaluation of the excision specimen. Due to the patients’
usual age and LM localization, nonsurgical treatments such as
topical imiquimod2 – combined with laser ablation,3 radiother-
apy or careful clinical follow-up – are sometimes considered.
The results of these treatments are uncertain. Many studies men-
tion clinical clearance with response rates up to 74% with topi-
cal imiquimod.2 One recent study showed histologically proven
complete clearance after topical imiquimod in only 37% of
cases.4 When these nonsurgical treatments are considered, the
fact that LMM can be underestimated based on initial biopsy
must be taken into account.
The aim of our study was to calculate the proportion of
biopsy-proven LMs that were upstaged to LMM after histological
evaluation of the excision specimen. Moreover, we have tested
the accuracy of the current pathology protocol.
All patients with histologically proven LM or LMM who were
diagnosed at our centre during the period January 2010 to
February 2017 were selected. Information on sex, age, size and
anatomical location of the lesion, diagnostics before treatment
(punch or incisional biopsy) and treatment method (including
the number of excision rounds in case of staged excision) was
retrieved from the clinical files. The histopathological diagnoses
(LM or LMM) before and after treatment were compared.
In addition, we tested our current protocol in 25 cases with
LM diagnosis based on staged excision. These patients were
randomly chosen for additional histopathological evaluation.
The tissue blocks (formalin fixed, paraffin embedded) with
LM were selected based on the corresponding haematoxylin
and eosin slides. Each block containing LM was cut for three
additional (deeper) levels to exclude possible invasion (i.e.
LMM). SPSS statistics 24 was used for the data analyses (IBM,
Armonk, NY, U.S.A.).
In the study period, 417 patients were diagnosed with histo-
logically proven LM or LMM at the Erasmus Medical Center. In
284 of 417 patients (681%) the initial biopsy showed LM, and
59 of 417 (141%) showed LMM (results not shown). In the
first group, 28 of 284 patients (99%) were treated not surgi-
cally but with topical imiquimod and laser. One patient was
excluded because the final diagnosis was melanoma in situ (re-
sults not shown). Of the remaining patients, in 232 of 255
(910%) the diagnosis of LM was confirmed after excision
(staged or conventional), and in 23 of 255 (90%) the LM was
reclassified as LMM or melanoma (Table 1). In the LM group
138 of 232 patients (595%) were female, and in the LMM
Table 1 Characteristics of patients diagnosed with lentigo maligna (LM) or lentigo maligna melanoma (LMM) between 2010 and February 2017
at the Erasmus Medical Center
Biopsy-proven LM treated
with surgery (n = 255)
LM after surgery
(n = 232, 910%)
LMM/melanoma after
surgery (n = 23, 90%)
Male, n (%) 94 (405) 14 (61)
Female, n (%) 138 (595) 9 (39)
Age (years), mean; median 711; 72 734; 73
Size category, n (%)
1 (< 1 cm) 44 (190) 3 (13)
2 (1–2 cm) 83 (358) 12 (52)
3 (2–5 cm) 47 (203) 2 (9)
4 (> 5 cm) 6 (26) 1 (4)
Unknown 52 (224) 5 (22)
Anatomical location, n (%)
Head and neck 201 (866) 18 (78)
Extremities 17 (73) 2 (9)
Trunk 14 (60) 3 (13)
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group nine of 23 (39%). At the time of diagnosis the mean ages
of patients in the LM and LMM groups were 71 and 73 years,
respectively. The LMs and LMMs were located mainly in the
head and neck region (respectively 866% and 78%) and had an
average size of 1–2 cm (Table 1). In the 25 cases of LM that
were used to test the current protocol we did not find invasive
melanoma after additional histopathological evaluation.
This study shows that 9% of biopsy-proven LMs turned out
to be LMM after complete excision (staged or conventional). A
previous epidemiological publication showed a cumulative risk
of LMM of 2–3% in patients with LM (histologically confirmed)
after 25 years of follow-up.1 If there is a clinical suspicion of
LM, current guidelines advise sampling with (punch or inci-
sional) biopsy, or for small lesions complete excision.5,6 Surgi-
cal excision is the first choice of treatment.5,6 The current study
adds that a biopsy alone may lead to underestimation of LMM.
A similar finding was reported before in a group of 46 patients
in whom an upgrade of 20% of LMs or melanomas in situ to
invasive melanoma was found.7
For melanoma in situ one study reported that 33% were
reclassified as invasive melanoma after additional histopatho-
logical evaluation of deeper sections.8 We could not confirm
this for LM in the 25 cases that we investigated.
In conclusion, there is a relatively high proportion (9%) of
biopsy-proven LMs that are reclassified to LMM or melanoma
after complete removal (either staged excision or conventional
excision). This should be taken into account in the therapeutic
decision making of LM. Additional histopathological evaluation
of the staged excision specimens does not contribute to higher
detection rates of LMM and is therefore not of added value to
the current protocol.
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